Provectus Biopharmaceuticals announced that data from preclinical research by the University of Calgary on oral administration of Provectus’s pharmaceutical-grade rose bengal for the treatments of solid tumor cancers were published in the open access journal of oncology Cancers. Titled Identification and In Vivo Validation of Unique Anti-Oncogenic Mechanisms Involving Protein Kinase Signaling and Autophagy Mediated by the Investigational Agent PV-10. The Narendran Lab provided preclinical proof-of-concept data supporting the efficacy of Provectus’s rose bengal in a panel of adult solid tumors. The Lab identified that the Company’s rose bengal downregulated WNK1 and Wnt signaling. In mice, the Narendran Lab also confirmed the clinical utility of Provectus’s rose bengal by intratumoral administration and demonstrated potential utility by oral administration.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PVCT:
- Provectus Pharmaceuticals Announces New Leadership and Strategy
- Provectus appoints Pershing as CEO, Rodrigues as President
- Provectus announces presentation of preclinical data on PV-10
- Provectus Pharmaceuticals Strikes Key Ophthalmology Therapy Deal
- Provectus announces worldwide license agreement with University of Miami